Mesenchymal Stem Cells Market Segmentation by Type (Human MSCs, Mouse MSCs, Rat MSCs, and Others); by Source (Bone Marrow, Umbilical Cord, Adipose Tissue, Molar Cells, and Others); and by Application (Drug Discovery, Injuries, Cardiovascular Myocardial Infarction, and Others) – Global Demand Analysis & Opportunity Outlook 2031
Buy Now
In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022. Purchasing power in the country is expected to fell nearly by 2.5%.
On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.
November 15, 2021: - Pluristem Therapeutics Inc. the leading biotechnology company, announced the commencement of its multinational Phase III multicenter research on muscle regeneration.
January 28, 2021: PromoCell GmbH to lead a research on immunotherapies through all human primary cells and blood & stem cells, including MHC class I genes HLA-A, -B, and -C.
Ans: The growing demand for regenerative treatment, along with growing awareness about stem cells are estimated to boost the market growth.
Ans: The market is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2022 – 2031.
Ans: The major players in the market are Merck Group, Genlantis Inc., Celprogen Inc., PromoCell GmbH, Cyagen Biosciences, Cytori Therapeutics Inc., Human Longevity Inc., Thermo Fisher Scientific, and others.
Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by type, source, application, and by region.
Ans: The umbilical cord segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities.
Ans: Very high cost of stem cell treatment is estimated to hamper the market growth.
Ans: The market in the North America region is estimated to provide more business opportunities for growth over the forecast period owing to the advancement in technology in the healthcare sector.
Submit Your Request For Proposal (RFP)
Submit RFP Buy Now Download Research Report Sample
